IL2RA and glioblastoma: In support of this, Mitchell, et al, recently demonstrated that immune responses were dramatically enhanced after dendritic cell vaccination in glioblastoma patients that received IL-2Rα mAb blockade (daclizumab, Roche Pharmaceuticals) and temozolomide chemotherapy [38].